SEC Form SC 13G/A filed

2/16/21 12:23:44 PM ET

Medical/Dental Instruments

Health Care

Get the next $WST alert in real time by email

SC 13G/A 1 wst13gadec20.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) WEST PHARMACEUTICAL SERVICES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 955306105 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,165,810 6. Shared Voting Power* 0 7. Sole Dispositive Power* 4,624,247 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,624,247 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 6.2% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: WEST PHARMACEUTICAL SERVICES INC Item 1(b) Address of Issuer's Principal Executive Offices: 530 HERMAN O. WEST DRIVE, EXTON, PENNSYLVANIA 19341 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 955306105 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 16, 2021 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2020

Get the next $WST alert in real time by email

Recent Analyst Ratings for

$WST

Date	Price Target	Rating	Analyst
2/7/2024	$323.00 → $536.00	Hold → Buy	Jefferies
6/16/2023	$390.00 → $405.00	Neutral → Buy	BofA Securities
4/11/2023	$330.00 → $400.00	Equal-Weight → Overweight	Stephens
12/14/2022	$250.00	Hold	Deutsche Bank
11/30/2022	$250.00	Neutral	UBS
10/28/2022	$385.00 → $250.00	Buy → Neutral	BofA Securities
7/30/2021	$350.00 → $475.00	Overweight	Keybanc

More analyst ratings

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for $WST

$WST Leadership Updates

Live Leadership Updates

Sotera Health Appoints Karen Flynn to Board of Directors

West Announces Executive Leadership Appointments

$WST Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

$WST Market Insights

Live Market Insights

West Pharmaceutical Services shares are trading lower after the company reported a Q2 earnings miss and cut its guidance.

West Pharmaceutical Services Expects 2024 Adjusted EPS Of $6.35-$6.65 Versus Prior Guidance Of $7.63-$7.88 And Consensus Of $7.74

West Pharmaceutical Services Updates Full-Year 2024 Net Sales Guidance To $2.87B-$2.9B Versus Prior Guidance Of $3B-$3.025B And Consensus Of $3.012B

$WST Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

VP & Treasurer Witherspoon Charles exercised 478 shares at a strike of $173.22 and sold $218,211 worth of shares (703 units at $310.40), decreasing direct ownership by 15% to 1,253 units (SEC Form 4)

SVP, Chief Technology Officer Abraham Silji covered exercise/tax liability with 180 shares and converted options into 458 shares, increasing direct ownership by 10% to 3,138 units (SEC Form 4)

VP & Treasurer Witherspoon Charles exercised 529 shares at a strike of $102.51 and sold $308,700 worth of shares (1,029 units at $300.00), decreasing direct ownership by 25% to 1,478 units (SEC Form 4)

$WST Press Releases

Fastest customizable press release news feed in the world

West to Participate in Upcoming Investor Conferences

West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend

West to Present on Large Volume Delivery Systems, Administration and Transfer Devices, and Prefillable Syringe Component Expertise at the PDA Conference

$WST SEC Filings

SEC Form 10-Q filed by West Pharmaceutical Services Inc.

West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 POS filed by West Pharmaceutical Services Inc.

$WST Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

West Pharm upgraded by Jefferies with a new price target

West Pharm upgraded by BofA Securities with a new price target

West Pharm upgraded by Stephens with a new price target

$WST Financials

Live finance-specific insights

West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend

West to Host Third-Quarter 2024 Conference Call

West Announces Second-Quarter 2024 Results

Recent Analyst Ratings for
$WST

$WST
Leadership Updates

$WST
Large Ownership Changes

$WST
Market Insights

$WST
Insider Trading

$WST
Press Releases

$WST
SEC Filings

$WST
Analyst Ratings

$WST
Financials